Orchestra Biomed Holdings Inc
OBIO
View Detailed Chart
3.910USD
+0.200+5.39%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
220.78MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+5.39%
5 Days
+12.03%
1 Month
-12.13%
6 Months
+48.11%
Year to Date
-5.78%
1 Year
-30.55%
View Detailed Chart
TradingKey Stock Score of Orchestra Biomed Holdings Inc
Currency: USD Updated: 2026-02-06Key Insights
Orchestra Biomed Holdings Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 108 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.43.In the medium term, the stock price is expected to remain stable.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Orchestra Biomed Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Orchestra Biomed Holdings Inc Highlights
StrengthsRisks
Orchestra BioMed Holdings, Inc. is a biomedical innovation company. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The Company develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.64M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.64M.
Overvalued
The company’s latest PE is -2.18, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 22.07M shares, increasing 9.49% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 3.14K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.02.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
13.429
Target Price
+261.96%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Orchestra Biomed Holdings Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Orchestra Biomed Holdings Inc Info
Orchestra BioMed Holdings, Inc. is a biomedical innovation company. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The Company develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.
Ticker SymbolOBIO
CompanyOrchestra Biomed Holdings Inc
CEOHochman (David P)
Website
Related Instruments
+2.98%
+0.07%
+1.60%
+2.48%
+0.31%
-1.14%
-0.05%
-2.35%
-1.78%
+2.65%
+2.59%
+2.03%
+2.01%
+2.38%
+1.74%
+0.16%
+0.78%
+1.72%
+0.59%
-2.02%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
69070.010
-900.120 (-1.29%)
282.580
+22.390 (+8.61%)
2057.630
+5.900 (+0.29%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
